Login / Signup

The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.

Virginie OryWilliam B KietzmanJacob BoeckelmanBhaskar V KallakuryAnton WellsteinPriscilla A FurthAnna T Riegel
Published in: Breast cancer research and treatment (2018)
Our data suggest that activation of the PPARγ pathway differentiates DCIS lesions and may be a useful approach to delay DCIS progression.
Keyphrases
  • insulin resistance
  • electronic health record
  • big data
  • fatty acid
  • type diabetes
  • metabolic syndrome
  • machine learning
  • artificial intelligence
  • deep learning